Suppr超能文献

使用体外和体内测试系统检测非那西丁的遗传毒性。

Assay of phenacetin genotoxicity using in vitro and in vivo test systems.

作者信息

De Flora S, Russo P, Pala M, Fassina G, Zunino A, Bennicelli C, Zanacchi P, Camoirano A, Parodi S

出版信息

J Toxicol Environ Health. 1985;16(3-4):355-77. doi: 10.1080/15287398509530747.

Abstract

Phenacetin was assayed in a battery of five short-term tests. (1) In a DNA-repair test using various Escherichia coli strains, the drug was not directly genotoxic nor did it induce nonreparable DNA damage in the presence of rat liver S9 fractions, while it was weakly active following activation with hamster liver S9. (2) In the Ames reversion test (strains TA97, TA98, TA100, and TA102 of Salmonella typhimurium, phenacetin reverted only TA100, and only in the presence of hamster liver S9. Mutagenicity was related to the concentration both of the drug and of the above metabolic system. There was no activation with hamster kidney S9, uninduced chicken liver S9, or with a variety of liver S9 preparations from rats treated with enzyme inducers (Aroclor 1254, phenobarbital, or 3-methylcholanthrene) and/or glutathione depletors (diethyl maleate or buthionine sulfoximine). Hamster liver S9 compared favorably to rat and even more to chicken liver S9 fractions also in activating various promutagens [3-amino-1-methyl-SH-pyrido (4,3-b)-indole, 2-aminofluorene, aflatoxin B1, benzo[a]pyrene, and benzo[a]pyrene-trans-7,8-diol] and in decreasing the mutagenicity of direct-acting compounds (4-nitroquinoline N-oxide and sodium dichromate). (3) Phenacetin was borderline positive in a forward mutation test (6-thioguanine resistance) in V79 cells, only in the presence of hamster liver S9, and gave negative results in the presence of rat liver S9 or without any metabolic system. (4) Following in vivo treatment, the alkaline elution assay did not reveal any DNA fragmentation in bone-marrow cells of ip-treated mice or in liver cells of rats treated by gavage. Apparent DNA damage was instead observed in the kidneys of rats receiving the drug by gavage or in the liver following ip administration. However, the effect was prevented (liver) or reduced (kidney) by preliminary perfusion of the organs, which discards (liver) or makes uncertain (kidney) the hypothesis of a true in vivo DNA damage. (5) Phenacetin ip induced in mouse bone-marrow cells a poor yet statistically significant increase in sister chromatid exchanges.

摘要

非那西丁在一组五项短期试验中进行了分析。(1)在一项使用多种大肠杆菌菌株的DNA修复试验中,该药物不是直接的基因毒性物质,在存在大鼠肝脏S9组分的情况下也不会诱导不可修复的DNA损伤,而在用仓鼠肝脏S9激活后它具有微弱活性。(2)在艾姆斯回复突变试验(鼠伤寒沙门氏菌TA97、TA98、TA100和TA102菌株)中,非那西丁仅使TA100回复突变,且仅在存在仓鼠肝脏S9的情况下。致突变性与药物和上述代谢系统的浓度都有关。用仓鼠肾脏S9、未诱导的鸡肝脏S9,或用酶诱导剂(多氯联苯1254、苯巴比妥或3 - 甲基胆蒽)和/或谷胱甘肽耗竭剂(马来酸二乙酯或丁硫氨酸亚砜胺)处理的大鼠的各种肝脏S9制剂处理时均未出现激活现象。在激活各种前诱变剂[3 - 氨基 - 1 - 甲基 - 5H - 吡啶并(4,3 - b) - 吲哚、2 - 氨基芴、黄曲霉毒素B1、苯并[a]芘和苯并[a]芘 - 反式 - 7,8 - 二醇]以及降低直接作用化合物(4 - 硝基喹啉N - 氧化物和重铬酸钠)的致突变性方面,仓鼠肝脏S9比大鼠肝脏S9甚至比鸡肝脏S9组分表现更优。(3)非那西丁在V79细胞的正向突变试验(6 - 硫鸟嘌呤抗性)中呈临界阳性,仅在存在仓鼠肝脏S9的情况下,而在存在大鼠肝脏S9或无任何代谢系统时结果为阴性。(4)在体内处理后,碱性洗脱试验未在腹腔注射处理的小鼠骨髓细胞或经口灌胃处理的大鼠肝细胞中发现任何DNA片段化。相反,在经口灌胃给药的大鼠肾脏或腹腔注射给药后的肝脏中观察到明显的DNA损伤。然而,通过对器官进行初步灌注,这种效应在肝脏中被阻止,在肾脏中被减轻,这使得肝脏中真正的体内DNA损伤的假设被排除,而肾脏中的情况变得不确定。(5)腹腔注射非那西丁在小鼠骨髓细胞中诱导了姐妹染色单体交换的轻微但具有统计学意义的增加。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验